>
Switch to:

Biomarin Pharmaceutical Piotroski F-Score

: 7 (As of Today)
View and export this data going back to 1999. Start your Free Trial

Good Sign:

Piotroski F-Score is 7, indicating very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biomarin Pharmaceutical has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Biomarin Pharmaceutical's Piotroski F-Score or its related term are showing as below:

NAS:BMRN' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 9
Current: 7

1
9

During the past 13 years, the highest Piotroski F-Score of Biomarin Pharmaceutical was 9. The lowest was 1. And the median was 4.


Biomarin Pharmaceutical Piotroski F-Score Historical Data

The historical data trend for Biomarin Pharmaceutical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 5.00 6.00 5.00

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 5.00 5.00 5.00 7.00

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biomarin Pharmaceutical Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep21) TTM:Last Year (Sep20) TTM:
Net Income was 22.099 + 17.371 + 12.941 + -36.494 = $16 Mil.
Cash Flow from Operations was -13.384 + 113.512 + 82.784 + 97.06 = $280 Mil.
Revenue was 452.123 + 486.069 + 501.693 + 408.742 = $1,849 Mil.
Gross Profit was 325.985 + 365.903 + 374.631 + 305.205 = $1,372 Mil.
Average Total Assets from the begining of this year (Sep20)
to the end of this year (Sep21) was
(6158.09 + 5848.02 + 5805.053 + 5898.496 + 5977.475) / 5 = $5937.4268 Mil.
Total Assets at the begining of this year (Sep20) was $6,158 Mil.
Long-Term Debt & Capital Lease Obligation was $1,078 Mil.
Total Current Assets was $2,312 Mil.
Total Current Liabilities was $515 Mil.
Net Income was 15.024 + 81.381 + -29.183 + 784.803 = $852 Mil.

Revenue was 454.438 + 502.043 + 429.485 + 476.784 = $1,863 Mil.
Gross Profit was 358.539 + 390.669 + 331.518 + 287.991 = $1,369 Mil.
Average Total Assets from the begining of last year (Sep19)
to the end of last year (Sep20) was
(4558.128 + 4690.039 + 4722.841 + 5302.11 + 6158.09) / 5 = $5086.2416 Mil.
Total Assets at the begining of last year (Sep19) was $4,558 Mil.
Long-Term Debt & Capital Lease Obligation was $1,074 Mil.
Total Current Assets was $2,739 Mil.
Total Current Liabilities was $855 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biomarin Pharmaceutical's current Net Income (TTM) was 16. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biomarin Pharmaceutical's current Cash Flow from Operations (TTM) was 280. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep20)
=15.917/6158.09
=0.00258473

ROA (Last Year)=Net Income/Total Assets (Sep19)
=852.025/4558.128
=0.18692433

Biomarin Pharmaceutical's return on assets of this year was 0.00258473. Biomarin Pharmaceutical's return on assets of last year was 0.18692433. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biomarin Pharmaceutical's current Net Income (TTM) was 16. Biomarin Pharmaceutical's current Cash Flow from Operations (TTM) was 280. ==> 280 > 16 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep20 to Sep21
=1078.093/5937.4268
=0.1815758

Gearing (Last Year: Sep20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep19 to Sep20
=1074.164/5086.2416
=0.21119013

Biomarin Pharmaceutical's gearing of this year was 0.1815758. Biomarin Pharmaceutical's gearing of last year was 0.21119013. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep21)=Total Current Assets/Total Current Liabilities
=2311.57/514.898
=4.48937459

Current Ratio (Last Year: Sep20)=Total Current Assets/Total Current Liabilities
=2738.979/854.693
=3.20463488

Biomarin Pharmaceutical's current ratio of this year was 4.48937459. Biomarin Pharmaceutical's current ratio of last year was 3.20463488. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biomarin Pharmaceutical's number of shares in issue this year was 183.214. Biomarin Pharmaceutical's number of shares in issue last year was 197.674. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1371.724/1848.627
=0.74202313

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1368.717/1862.75
=0.73478298

Biomarin Pharmaceutical's gross margin of this year was 0.74202313. Biomarin Pharmaceutical's gross margin of last year was 0.73478298. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep20)
=1848.627/6158.09
=0.30019487

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep19)
=1862.75/4558.128
=0.40866557

Biomarin Pharmaceutical's asset turnover of this year was 0.30019487. Biomarin Pharmaceutical's asset turnover of last year was 0.40866557. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+1+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biomarin Pharmaceutical has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Biomarin Pharmaceutical  (NAS:BMRN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biomarin Pharmaceutical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)